Description
The EP PerMed partnership - supported by the European Union under Horizon Europe (Grant Agreement No 101137129) - launches its first "Twinning Call 2026", aimed at promoting effective transfer of established personalised medicine (PM) solutions across institutions in different countries. Through structured "Twinning" partnerships, a "Donor" institution sharing an already-implemented PM approach collaborates with one or two "Receiver" institutions to adapt, adopt or implement that PM solution in their own context. The call supports projects with a duration between 6 and 12 months. The goal is that by the end of the twinning project, the Receiver institution is able to initiate, partially or fully adopt the PM approach, embedding it in their own healthcare delivery.

Eligible activities cover implementation of care pathways, technological PM solutions, diagnostic or therapeutic approaches, patient management, prevention strategies, follow-up systems, etc.-provided they already exist in the Donor institution. Importantly, the call does not fund proposals that only aim to exchange general PM knowledge or for pure research; there must be a clear (direct or indirect) impact on patient care. Solutions must be mature (for technologies, typically TRL 9 and CE-marked if relevant).

Objectives
Enable cross-border transfer and implementation of proven personalised medicine solutions in new healthcare settings, thereby scaling up PM practices and improving patient care across institutions.

Budget

Funding available per Twinning awarded project is up to 50,000 EUR (fifty thousand Euros) including overheads. Reimbursement rate is 100%

• Applicants must be legally registered organisations in a Horizon Europe Member State or Associated Country.

• Only health and care provider organisations (e.g. hospitals, regional or national healthcare providers) are eligible as applicants.

• The consortium must consist of exactly one Donor institution and one or two Receiver institutions (2-3 partners total) from at least two different countries, which must be legally and financially independent.

• The personalised medicine solution must already be mature and successfully implemented in the Donor institution; technological solutions should correspond to TRL 9 and be CE-marked if applicable.

• The project must focus on implementation; pure research projects, preliminary studies, policy-only initiatives, awareness campaigns, regulatory or guideline development alone, or marketing-oriented activities are not eligible.

• Eligible costs are limited to activities supporting the twinning process (e.g. meetings, exchanges, travel, professional services). Costs related to equipment purchase or further development of the PM solution are not eligible.

• Applications and project activities must be submitted and carried out in English.

In case of interest, please click on "m'interessa" and we will contact you.